Diabetes - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols DLG4 and IL13RA1	Name 1 discs large MAGUK scaffold protein 4	Name2 interleukin 13 receptor subunit alpha 1	Pathway 1 Signaling by ERBB4 Trafficking of AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor NrCAM interactions Activation of Ca-permeable Kainate Receptor RHO GTPases activate CIT RAF/MAP kinase cascade LGI-ADAM interactions Neurexins and neuroligins Neurexins and neuroligins Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Pathway 2 Interleukin-4 and Interleukin-13 signaling	Drugs 1 Guanidine Guanosine-5'-Monophosphate	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols KPNA4 and ZRANB3	Name 1 karyopherin subunit alpha 4	Name2 zinc finger RANBP2-type containing 3	Pathway 1 ISG15 antiviral mechanism NS1 Mediated Effects on Host Pathways	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols S100P and IL27	Name 1 S100 calcium binding protein P	Name2 interleukin 27	Pathway 1 Neutrophil degranulation	Pathway 2 Interleukin-27 signaling Interleukin-27 signaling	Drugs 1 Cromoglicic acid	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols TIAM1 and OSBPL1A	Name 1 TIAM Rac1 associated GEF 1	Name2 oxysterol binding protein like 1A	Pathway 1 NRAGE signals death through JNK EPHB-mediated forward signaling EPH-ephrin mediated repulsion of cells G alpha (12/13) signalling events RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RAC3 GTPase cycle Activated NTRK2 signals through CDK5	Pathway 2 Synthesis of bile acids and bile salts MHC class II antigen presentation	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols TIAM1 and ABCC5	Name 1 TIAM Rac1 associated GEF 1	Name2 ATP binding cassette subfamily C member 5	Pathway 1 NRAGE signals death through JNK EPHB-mediated forward signaling EPH-ephrin mediated repulsion of cells G alpha (12/13) signalling events RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RAC3 GTPase cycle Activated NTRK2 signals through CDK5	Pathway 2 Hyaluronan metabolism ABC-family proteins mediated transport Azathioprine ADME Paracetamol ADME	Drugs 1	Drugs 2 Curcumin Curcumin sulfate	Diseases 1	Diseases 2
Novel Novel	Symbols HNRNPL and IL7R	Name 1 heterogeneous nuclear ribonucleoprotein L	Name2 interleukin 7 receptor	Pathway 1 mRNA Splicing - Major Pathway Processing of Capped Intron-Containing Pre-mRNA	Pathway 2 Interleukin-7 signaling Interleukin-7 signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis	Drugs 1 Copper	Drugs 2	Diseases 1	Diseases 2 T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
Novel Novel	Symbols IFI35 and EML2	Name 1 interferon induced protein 35	Name2 EMAP like 2	Pathway 1 Interferon alpha/beta signaling	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols SYN2 and YWHAZ	Name 1 synapsin II	Name2 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Pathway 1 Serotonin Neurotransmitter Release Cycle Dopamine Neurotransmitter Release Cycle	Pathway 2 Activation of BAD and translocation to mitochondria Translocation of SLC2A4 (GLUT4) to the plasma membrane Deactivation of the beta-catenin transactivating complex Rap1 signalling GP1b-IX-V activation signalling KSRP (KHSRP) binds and destabilizes mRNA Interleukin-3, Interleukin-5 and GM-CSF signaling RHO GTPases activate PKNs TP53 Regulates Metabolic Genes Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex NOTCH4 Activation and Transmission of Signal to the Nucleus Negative regulation of NOTCH4 signaling Regulation of localization of FOXO transcription factors SARS-CoV-1 targets host intracellular signalling and regulatory pathways SARS-CoV-2 targets host intracellular signalling and regulatory pathways Transcriptional and post-translational regulation of MITF-M expression and activity	Drugs 1	Drugs 2 Phenethyl Isothiocyanate	Diseases 1	Diseases 2
Novel Novel	Symbols FXR1 and KIF9	Name 1 FMR1 autosomal homolog 1	Name2 kinesin family member 9	Pathway 1 Signaling by BRAF and RAF1 fusions	Pathway 2 COPI-dependent Golgi-to-ER retrograde traffic Kinesins Kinesins	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FXR1 and CEP89	Name 1 FMR1 autosomal homolog 1	Name2 centrosomal protein 89	Pathway 1 Signaling by BRAF and RAF1 fusions	Pathway 2 Anchoring of the basal body to the plasma membrane	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FXR1 and INA	Name 1 FMR1 autosomal homolog 1	Name2 internexin neuronal intermediate filament protein alpha	Pathway 1 Signaling by BRAF and RAF1 fusions	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FXR1 and TRIOBP	Name 1 FMR1 autosomal homolog 1	Name2 TRIO and F-actin binding protein	Pathway 1 Signaling by BRAF and RAF1 fusions	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CDKN1C and LIMK1	Name 1 cyclin dependent kinase inhibitor 1C	Name2 LIM domain kinase 1	Pathway 1 Cyclin D associated events in G1 Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	Pathway 2 Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation EPHB-mediated forward signaling Sema3A PAK dependent Axon repulsion Sema3A PAK dependent Axon repulsion Sema4D induced cell migration and growth-cone collapse RHO GTPases Activate ROCKs RHO GTPases activate PAKs	Drugs 1	Drugs 2 Dabrafenib Fostamatinib	Diseases 1 Beckwith-Wiedemann syndrome Adrenal carcinoma	Diseases 2
Novel Novel	Symbols NEUROD1 and RREB1	Name 1 neuronal differentiation 1	Name2 ras responsive element binding protein 1	Pathway 1 Regulation of gene expression in beta cells Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Maturity onset diabetes of the young (MODY)	Diseases 2
Novel Novel	Symbols DCTN1 and KIF11	Name 1 dynactin subunit 1	Name2 kinesin family member 11	Pathway 1 MHC class II antigen presentation HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand XBP1(S) activates chaperone genes COPI-mediated anterograde transport COPI-independent Golgi-to-ER retrograde traffic Signaling by ALK fusions and activated point mutants	Pathway 2 MHC class II antigen presentation COPI-dependent Golgi-to-ER retrograde traffic Kinesins	Drugs 1	Drugs 2 3-[(5s)-1-Acetyl-3-(2-Chlorophenyl)-4,5-Dihydro-1h-Pyrazol-5-Yl]Phenol Monastrol Filanesib (4R)-4-(3-HYDROXYPHENYL)-N,N,7,8-TETRAMETHYL-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE N,N-DIETHYL-2-[(2-THIENYLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE (5R)-N,N-DIETHYL-5-METHYL-2-[(THIOPHEN-2-YLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE MK-0731 [(4R)-4-(3-HYDROXYPHENYL)-1,6-DIMETHYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL](PHENYL)METHANONE (2S)-4-(2,5-DIFLUOROPHENYL)-N-METHYL-2-PHENYL-N-PIPERIDIN-4-YL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE (1S)-1-CYCLOPROPYL-2-[(2S)-4-(2,5-DIFLUOROPHENYL)-2-PHENYL-2,5-DIHYDRO-1H-PYRROL-1-YL]-2-OXOETHANAMINE (2S)-4-(2,5-DIFLUOROPHENYL)-N,N-DIMETHYL-2-PHENYL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE (5S)-5-(3-AMINOPROPYL)-3-(2,5-DIFLUOROPHENYL)-N-ETHYL-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE	Diseases 1 Perry syndrome Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease Distal hereditary motor neuropathies (dHMN)	Diseases 2
Novel Novel	Symbols HAP1 and ZNF648	Name 1 huntingtin associated protein 1	Name2 zinc finger protein 648	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols BPTF and MAZ	Name 1 bromodomain PHD finger transcription factor	Name2 MYC associated zinc finger protein	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols BAD and BRAF	Name 1 BCL2 associated agonist of cell death	Name2 B-Raf proto-oncogene, serine/threonine kinase	Pathway 1 Activation of BAD and translocation to mitochondria Activation of BAD and translocation to mitochondria BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members NRAGE signals death through JNK AKT phosphorylates targets in the cytosol Constitutive Signaling by AKT1 E17K in Cancer	Pathway 2 Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling	Drugs 1 Navitoclax	Drugs 2 Sorafenib XL281 RAF-265 PLX-4720 N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib Encorafenib Fostamatinib Ripretinib	Diseases 1	Diseases 2 Malignant melanoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer
Novel Novel	Symbols BAD and PIM3	Name 1 BCL2 associated agonist of cell death	Name2 Pim-3 proto-oncogene, serine/threonine kinase	Pathway 1 Activation of BAD and translocation to mitochondria Activation of BAD and translocation to mitochondria BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members NRAGE signals death through JNK AKT phosphorylates targets in the cytosol Constitutive Signaling by AKT1 E17K in Cancer	Pathway 2	Drugs 1 Navitoclax	Drugs 2 Fostamatinib	Diseases 1	Diseases 2
Novel Novel	Symbols MPP3 and FAM171B	Name 1 MAGUK p55 scaffold protein 3	Name2 family with sequence similarity 171 member B	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols DLG4 and IL13RA1	Name 1 discs large MAGUK scaffold protein 4	Name2 interleukin 13 receptor subunit alpha 1	Pathway 1 Signaling by ERBB4 Trafficking of AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor NrCAM interactions Activation of Ca-permeable Kainate Receptor RHO GTPases activate CIT RAF/MAP kinase cascade LGI-ADAM interactions Neurexins and neuroligins Neurexins and neuroligins Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Pathway 2 Interleukin-4 and Interleukin-13 signaling	Drugs 1 Guanidine Guanosine-5'-Monophosphate	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols KPNA4 and ZRANB3	Name 1 karyopherin subunit alpha 4	Name2 zinc finger RANBP2-type containing 3	Pathway 1 ISG15 antiviral mechanism NS1 Mediated Effects on Host Pathways	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols S100P and IL27	Name 1 S100 calcium binding protein P	Name2 interleukin 27	Pathway 1 Neutrophil degranulation	Pathway 2 Interleukin-27 signaling Interleukin-27 signaling	Drugs 1 Cromoglicic acid	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols TIAM1 and OSBPL1A	Name 1 TIAM Rac1 associated GEF 1	Name2 oxysterol binding protein like 1A	Pathway 1 NRAGE signals death through JNK EPHB-mediated forward signaling EPH-ephrin mediated repulsion of cells G alpha (12/13) signalling events RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RAC3 GTPase cycle Activated NTRK2 signals through CDK5	Pathway 2 Synthesis of bile acids and bile salts MHC class II antigen presentation	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols TIAM1 and ABCC5	Name 1 TIAM Rac1 associated GEF 1	Name2 ATP binding cassette subfamily C member 5	Pathway 1 NRAGE signals death through JNK EPHB-mediated forward signaling EPH-ephrin mediated repulsion of cells G alpha (12/13) signalling events RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RAC3 GTPase cycle Activated NTRK2 signals through CDK5	Pathway 2 Hyaluronan metabolism ABC-family proteins mediated transport Azathioprine ADME Paracetamol ADME	Drugs 1	Drugs 2 Curcumin Curcumin sulfate	Diseases 1	Diseases 2
Novel	Symbols HNRNPL and IL7R	Name 1 heterogeneous nuclear ribonucleoprotein L	Name2 interleukin 7 receptor	Pathway 1 mRNA Splicing - Major Pathway Processing of Capped Intron-Containing Pre-mRNA	Pathway 2 Interleukin-7 signaling Interleukin-7 signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis	Drugs 1 Copper	Drugs 2	Diseases 1	Diseases 2 T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
Novel	Symbols IFI35 and EML2	Name 1 interferon induced protein 35	Name2 EMAP like 2	Pathway 1 Interferon alpha/beta signaling	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols SYN2 and YWHAZ	Name 1 synapsin II	Name2 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Pathway 1 Serotonin Neurotransmitter Release Cycle Dopamine Neurotransmitter Release Cycle	Pathway 2 Activation of BAD and translocation to mitochondria Translocation of SLC2A4 (GLUT4) to the plasma membrane Deactivation of the beta-catenin transactivating complex Rap1 signalling GP1b-IX-V activation signalling KSRP (KHSRP) binds and destabilizes mRNA Interleukin-3, Interleukin-5 and GM-CSF signaling RHO GTPases activate PKNs TP53 Regulates Metabolic Genes Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex NOTCH4 Activation and Transmission of Signal to the Nucleus Negative regulation of NOTCH4 signaling Regulation of localization of FOXO transcription factors SARS-CoV-1 targets host intracellular signalling and regulatory pathways SARS-CoV-2 targets host intracellular signalling and regulatory pathways Transcriptional and post-translational regulation of MITF-M expression and activity	Drugs 1	Drugs 2 Phenethyl Isothiocyanate	Diseases 1	Diseases 2
Novel	Symbols FXR1 and KIF9	Name 1 FMR1 autosomal homolog 1	Name2 kinesin family member 9	Pathway 1 Signaling by BRAF and RAF1 fusions	Pathway 2 COPI-dependent Golgi-to-ER retrograde traffic Kinesins Kinesins	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FXR1 and CEP89	Name 1 FMR1 autosomal homolog 1	Name2 centrosomal protein 89	Pathway 1 Signaling by BRAF and RAF1 fusions	Pathway 2 Anchoring of the basal body to the plasma membrane	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FXR1 and INA	Name 1 FMR1 autosomal homolog 1	Name2 internexin neuronal intermediate filament protein alpha	Pathway 1 Signaling by BRAF and RAF1 fusions	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FXR1 and TRIOBP	Name 1 FMR1 autosomal homolog 1	Name2 TRIO and F-actin binding protein	Pathway 1 Signaling by BRAF and RAF1 fusions	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CDKN1C and LIMK1	Name 1 cyclin dependent kinase inhibitor 1C	Name2 LIM domain kinase 1	Pathway 1 Cyclin D associated events in G1 Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	Pathway 2 Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation EPHB-mediated forward signaling Sema3A PAK dependent Axon repulsion Sema3A PAK dependent Axon repulsion Sema4D induced cell migration and growth-cone collapse RHO GTPases Activate ROCKs RHO GTPases activate PAKs	Drugs 1	Drugs 2 Dabrafenib Fostamatinib	Diseases 1 Beckwith-Wiedemann syndrome Adrenal carcinoma	Diseases 2
Novel	Symbols NEUROD1 and RREB1	Name 1 neuronal differentiation 1	Name2 ras responsive element binding protein 1	Pathway 1 Regulation of gene expression in beta cells Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Maturity onset diabetes of the young (MODY)	Diseases 2
Novel	Symbols DCTN1 and KIF11	Name 1 dynactin subunit 1	Name2 kinesin family member 11	Pathway 1 MHC class II antigen presentation HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand XBP1(S) activates chaperone genes COPI-mediated anterograde transport COPI-independent Golgi-to-ER retrograde traffic Signaling by ALK fusions and activated point mutants	Pathway 2 MHC class II antigen presentation COPI-dependent Golgi-to-ER retrograde traffic Kinesins	Drugs 1	Drugs 2 3-[(5s)-1-Acetyl-3-(2-Chlorophenyl)-4,5-Dihydro-1h-Pyrazol-5-Yl]Phenol Monastrol Filanesib (4R)-4-(3-HYDROXYPHENYL)-N,N,7,8-TETRAMETHYL-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE N,N-DIETHYL-2-[(2-THIENYLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE (5R)-N,N-DIETHYL-5-METHYL-2-[(THIOPHEN-2-YLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE MK-0731 [(4R)-4-(3-HYDROXYPHENYL)-1,6-DIMETHYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL](PHENYL)METHANONE (2S)-4-(2,5-DIFLUOROPHENYL)-N-METHYL-2-PHENYL-N-PIPERIDIN-4-YL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE (1S)-1-CYCLOPROPYL-2-[(2S)-4-(2,5-DIFLUOROPHENYL)-2-PHENYL-2,5-DIHYDRO-1H-PYRROL-1-YL]-2-OXOETHANAMINE (2S)-4-(2,5-DIFLUOROPHENYL)-N,N-DIMETHYL-2-PHENYL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE (5S)-5-(3-AMINOPROPYL)-3-(2,5-DIFLUOROPHENYL)-N-ETHYL-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE	Diseases 1 Perry syndrome Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease Distal hereditary motor neuropathies (dHMN)	Diseases 2
Novel	Symbols HAP1 and ZNF648	Name 1 huntingtin associated protein 1	Name2 zinc finger protein 648	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols BPTF and MAZ	Name 1 bromodomain PHD finger transcription factor	Name2 MYC associated zinc finger protein	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols BAD and BRAF	Name 1 BCL2 associated agonist of cell death	Name2 B-Raf proto-oncogene, serine/threonine kinase	Pathway 1 Activation of BAD and translocation to mitochondria Activation of BAD and translocation to mitochondria BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members NRAGE signals death through JNK AKT phosphorylates targets in the cytosol Constitutive Signaling by AKT1 E17K in Cancer	Pathway 2 Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling	Drugs 1 Navitoclax	Drugs 2 Sorafenib XL281 RAF-265 PLX-4720 N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib Encorafenib Fostamatinib Ripretinib	Diseases 1	Diseases 2 Malignant melanoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer
Novel	Symbols BAD and PIM3	Name 1 BCL2 associated agonist of cell death	Name2 Pim-3 proto-oncogene, serine/threonine kinase	Pathway 1 Activation of BAD and translocation to mitochondria Activation of BAD and translocation to mitochondria BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members NRAGE signals death through JNK AKT phosphorylates targets in the cytosol Constitutive Signaling by AKT1 E17K in Cancer	Pathway 2	Drugs 1 Navitoclax	Drugs 2 Fostamatinib	Diseases 1	Diseases 2
Novel	Symbols MPP3 and FAM171B	Name 1 MAGUK p55 scaffold protein 3	Name2 family with sequence similarity 171 member B	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2

Page 36 out of 58 pages

Search Results : Diabetes